[go: up one dir, main page]

BRPI0408365B8 - compostos heterocíclicos de imunomodulação - Google Patents

compostos heterocíclicos de imunomodulação

Info

Publication number
BRPI0408365B8
BRPI0408365B8 BRPI0408365A BRPI0408365A BRPI0408365B8 BR PI0408365 B8 BRPI0408365 B8 BR PI0408365B8 BR PI0408365 A BRPI0408365 A BR PI0408365A BR PI0408365 A BRPI0408365 A BR PI0408365A BR PI0408365 B8 BRPI0408365 B8 BR PI0408365B8
Authority
BR
Brazil
Prior art keywords
optionally substituted
alk
alkyl
radical
heterocyclic
Prior art date
Application number
BRPI0408365A
Other languages
English (en)
Inventor
Richard Mathews Ian
Original Assignee
Avidex Ltd
Medigene Ag
Medigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0305876A external-priority patent/GB0305876D0/en
Priority claimed from GB0319429A external-priority patent/GB0319429D0/en
Application filed by Avidex Ltd, Medigene Ag, Medigene Ltd filed Critical Avidex Ltd
Publication of BRPI0408365A publication Critical patent/BRPI0408365A/pt
Publication of BRPI0408365B1 publication Critical patent/BRPI0408365B1/pt
Publication of BRPI0408365B8 publication Critical patent/BRPI0408365B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

compostos heterocíclicos de imunomodulação. a presente invenção refere-se a compostos da fórmula (i) são inibidores de cd80 e úteis na terapia de imunomodulação: (i) r1 e r3 representam, independentemente h; f, ci; br; -no2; -cn; c1-6 alquila opcionalmente substituída por f ou ci; ou c1-c6 alcóxi, opcionalmente substituído por f; r4 representa um grupo de ácido carboxílico (-cooh) ou um éster do mesmo, ou -c(=o)nr6r7, -nr7c(=o)r6, -nr7c(=o)or6, -nhc(=o)nr7r6 ou nhc(=s)nr7r6 onde: r6 representa h ou um radical da fórmula -(alq)m-q, onde: m é 0 ou 1; alq é um c1-c12 alquileno divalente, opcionalmente substituído, linear ou ramificado, ou radical c2-c12 alquenileno ou c2-c12 alquinileno ou um radical divalente c3-c12 carboxílico, qualquer um dos quais pode conter uma ou mais das ligações -o-, -s- ou -n(r8)- onde r8 representa h ou c1-c4 alquila, c3-c4 alquenila, c3-c4 alquinila ou c3-c6 cicloalquila e q representa h; -nr9r10 onde r9 e r10 representam, independentemente h; c1-c4 alquila; c3-c4 alquenila; c3-c4 alquinila; c3-c6 cicloalquila; um grupo éster; um grupo carbocíclico ou heterocíclico opcionalmente substituído; ou r9 e r10 formam um anel, quando tomados em conjunto com o nitrogênio ao qual estão anexados, o anel sendo opcionalmente substituído; e r7 representa h ou c1-c6 alquila; ou quando tomado em conjunto com o átomo ou átomos ao qual está ligado, ele é anexado a r6 e r7 formando um anal monocíclico opcionalmente substituído, possuindo 5, 6 ou 7 átomos no anel; e x representa uma ligação ou radical divalente da fórmula -(z)n(alq)- ou -(alq)-(z)n- onde z representa -o-, -s- ou -nh-, alq é conforme definido em relação a r6 e n é 0 ou 1.
BRPI0408365A 2003-03-14 2004-03-10 compostos heterocíclicos de imunomodulação BRPI0408365B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0305876A GB0305876D0 (en) 2003-03-14 2003-03-14 Immuno inhibitory heterocyclic compounds
GB0319429A GB0319429D0 (en) 2003-08-19 2003-08-19 Immuno Inhibitory Heterocyclic compounds
PCT/GB2004/001008 WO2004081011A1 (en) 2003-03-14 2004-03-10 Immunomodulating heterocyclic compounds

Publications (3)

Publication Number Publication Date
BRPI0408365A BRPI0408365A (pt) 2006-03-21
BRPI0408365B1 BRPI0408365B1 (pt) 2018-11-21
BRPI0408365B8 true BRPI0408365B8 (pt) 2021-05-25

Family

ID=32992598

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408365A BRPI0408365B8 (pt) 2003-03-14 2004-03-10 compostos heterocíclicos de imunomodulação

Country Status (19)

Country Link
US (3) US7276505B2 (pt)
EP (2) EP2284172A1 (pt)
JP (1) JP4892338B2 (pt)
KR (1) KR101133959B1 (pt)
AT (1) ATE489388T1 (pt)
BR (1) BRPI0408365B8 (pt)
CA (1) CA2519063C (pt)
DE (1) DE602004030225D1 (pt)
DK (1) DK1603917T3 (pt)
EA (2) EA009680B1 (pt)
EC (1) ECSP056104A (pt)
IL (1) IL170389A (pt)
MX (1) MXPA05009667A (pt)
NO (1) NO332136B1 (pt)
NZ (1) NZ541973A (pt)
PL (2) PL1603917T3 (pt)
PT (1) PT1603917E (pt)
SI (1) SI1603917T1 (pt)
WO (1) WO2004081011A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2284172A1 (en) * 2003-03-14 2011-02-16 MediGene Ltd. Immunomodulating heterocyclic compounds
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
CA2576256C (en) * 2004-08-09 2012-01-03 Avidex Limited Immunomodulating oxopyrrazolocinnolines as cd80 inhibitors
CA2618888A1 (en) * 2005-08-10 2007-02-15 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition
WO2007108936A2 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
WO2007136668A2 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
US20100093867A1 (en) * 2006-07-05 2010-04-15 Ryoichi Matsuda Method Of Treating Genetic Disease Caused By Nonsense Mutation
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
JP2010533725A (ja) 2007-07-16 2010-10-28 ワイス・エルエルシー ヒスタミン‐３（ｈ３）受容体としてのアミノアルキルアゾール化合物
EP2020404A1 (en) * 2007-08-01 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Cyanomethyl substituted N-Acyl Tryptamines
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2676666A1 (en) 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Compounds for use in diagnosis or therapy of vulnerable atherosclerotic plaques
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
AU2015315177A1 (en) * 2014-09-10 2017-03-16 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
EP3558992A4 (en) * 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB629412A (en) 1946-12-24 1949-09-20 Geigy Ag J R Manufacture of metallisable monoazo dyestuffs of the pyrazolone series
US3576637A (en) * 1967-04-20 1971-04-27 Konishiroku Photo Ind Lith-type of emulsion containing pyrozolone
JPS61161285A (ja) * 1984-12-28 1986-07-21 ルセル−ユクラフ ピラゾロ〔４，３−ｃ〕シンノリン−３−オンの誘導体、それらの塩類、これらの製造法、薬剤としての使用、これらを含有する組成物及び中間体生成物
US4591589A (en) * 1985-01-16 1986-05-27 Roussel Uclaf 2-aryl pyrazolo[4,3-c]cinnolin-3-ones
DE3626221A1 (de) 1986-08-02 1988-02-04 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial zur herstellung farbiger aufsichtsbilder
EP0269030B1 (en) 1986-11-20 1994-05-04 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
GB9713707D0 (en) 1997-06-27 1997-09-03 Merck Sharp & Dohme Therapeutic agents
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds
WO2003004485A1 (en) 2001-07-05 2003-01-16 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
US7566711B2 (en) * 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
CN100347173C (zh) 2002-11-22 2007-11-07 活跃生物技术股份公司 具有免疫调制活性的吡唑并喹啉
AU2003287129A1 (en) 2002-12-16 2004-07-09 Active Biotech Ab Tetracyclic immunomodulatory compounds
EP2284172A1 (en) 2003-03-14 2011-02-16 MediGene Ltd. Immunomodulating heterocyclic compounds
GB0325644D0 (en) * 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
GB0411770D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Immuno inhibitory heterocyclic compouds
CA2576256C (en) * 2004-08-09 2012-01-03 Avidex Limited Immunomodulating oxopyrrazolocinnolines as cd80 inhibitors
US20060221590A1 (en) * 2005-03-31 2006-10-05 Edoardo Campini System and method for Advanced Mezzanine Card connection
GB0603522D0 (en) 2006-02-22 2006-04-05 Avidex Ltd Kinase inhibition

Also Published As

Publication number Publication date
US7598247B2 (en) 2009-10-06
EP2284172A1 (en) 2011-02-16
EP1603917A1 (en) 2005-12-14
PL383655A1 (pl) 2008-04-14
NO332136B1 (no) 2012-07-02
EA009680B1 (ru) 2008-02-28
EP1603917B1 (en) 2010-11-24
BRPI0408365A (pt) 2006-03-21
KR20050121681A (ko) 2005-12-27
EA200702435A1 (ru) 2008-06-30
US7276505B2 (en) 2007-10-02
DE602004030225D1 (de) 2011-01-05
NO20054710L (no) 2005-12-13
NZ541973A (en) 2009-06-26
ATE489388T1 (de) 2010-12-15
KR101133959B1 (ko) 2012-04-09
NO20054710D0 (no) 2005-10-13
WO2004081011A1 (en) 2004-09-23
PT1603917E (pt) 2011-02-04
US20070021428A1 (en) 2007-01-25
HK1090921A1 (zh) 2007-01-05
EA200501370A1 (ru) 2006-08-25
CA2519063C (en) 2011-05-10
US20090312334A1 (en) 2009-12-17
JP2006520372A (ja) 2006-09-07
BRPI0408365B1 (pt) 2018-11-21
EA014080B1 (ru) 2010-08-30
IL170389A (en) 2013-08-29
CA2519063A1 (en) 2004-09-23
PL1603917T3 (pl) 2011-12-30
SI1603917T1 (sl) 2011-04-29
US8309552B2 (en) 2012-11-13
ECSP056104A (es) 2006-03-01
US20080045527A1 (en) 2008-02-21
AU2004220310A1 (en) 2004-09-23
DK1603917T3 (da) 2011-02-28
JP4892338B2 (ja) 2012-03-07
MXPA05009667A (es) 2006-01-27

Similar Documents

Publication Publication Date Title
BRPI0408365B8 (pt) compostos heterocíclicos de imunomodulação
ES2184280T3 (es) Compuestos de indol como inhibidores de cox-2'.
DK0650960T3 (da) Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
DK1265606T3 (da) Celleadhæsionsinhibitorer
PE20090151A1 (es) Derivados de pirimidinona y metodos para su uso
NO20076006L (no) Acetylenderivater
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
BR0012697A (pt) Inibidores da diferenciação de th2
BRPI0412439A (pt) compostos e composições compreendendo esteróis e/ou estanóis e inibidores de biossìntese de colesterol e uso dos mesmos no tratamento ou prevenção de uma variedade de doenças e condições
PE20061076A1 (es) Derivados de isoxazolina como agentes inhibidores de la caspasa y procedimiento para su preparacion
ECSP077270A (es) Ácidos de tiazolo - naftilo
AR042067A1 (es) Derivados de anilinopirazol utiles en el tratamiento de la diabetes
CO6280421A2 (es) Bifosfatos de alquilo de 2 a 5 atomos de carbonoimidazol
BR0309188A (pt) Compostos pirazolo como agentes antiinflamatórios e analgésicos
AR041882A1 (es) Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
CR7249A (es) Derivados de diamina, proceso para producir los derivados de diamina, y funguicidas que contienen los derivados de diamina como ingrediente activo
DE60309251D1 (de) Verfahren zur Herstellung von Donepezil
DK295989A (da) Insekt- og miderepellanter
EP1914229A4 (en) NOVEL CERCOSPORAMIDE DERIVATIVES
AR035003A1 (es) Derivados de propanolamina relacionados con acidos biliares, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo para la preparacion de medicamentos
DE602005025464D1 (de) Aminosäure- und peptid-konjugate von arylalkylsäuren zur verwendung in der kosmetik
TW200740428A (en) Substituted propanamide derivatives and pharmaceutical compositions thereof
HUP0303020A2 (hu) Androgén 7-szubsztituált 11-halogénezett szteroidok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MEDIGENE LTD. (GB)

Free format text: NOME ALTERADO DE: AVIDEX LIMITED

B25A Requested transfer of rights approved

Owner name: MEDIGENE AG (DE)

Free format text: TRANSFERIDO DE: MEDIGENE LTD.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.